ME3: A Drug Target for Neurodegenerative Diseases (G10873)

Target Name: ME3

NCBI ID: G10873

Content of Review Report on ME3 Target / Biomarker

ME3

ME3: A Drug Target for Neurodegenerative Diseases

ME3 (Mitochondrial Encephalomyelitis Enteralis) is a rare, progressive, demyelinating disease of the brain caused by a deficiency of the protein tau. It is characterized by the progressive degeneration of the mitochondria, which are responsible for generating energy for the brain, leading to a progressive loss of cognitive and motor function.

ME3 is a drug target (or biomarker) of great interest to researchers because it provides a unique opportunity to study the role of mitochondria in the development and progression of neurodegenerative diseases. The study of ME3 has the potential to lead to the development of new treatments for a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

One of the main goals of research into ME3 is to understand how the defect in the protein tau contributes to the progressive degeneration of the brain. This is an important step in the development of new treatments because it provides insight into the underlying mechanisms of the disease.

Research has shown that tau is a protein that is involved in the structure and function of mitochondria. It is thought to play a role in the transfer of energy from the mitochondria to the brain cells, which is crucial for the proper functioning of the brain.

In people with ME3, the levels of tau in the brain are significantly decreased, which leads to a progressive loss of energy production and an accumulation of waste products in the brain. This accumulation of waste products is thought to contribute to the progressive degeneration of the brain and the development of the symptoms of ME3.

One of the key challenges in studying ME3 is the difficulty of studying a disease that affects only a small number of people. This is because the development of new treatments for neurodegenerative diseases is often difficult due to the limited number of patients available for research. However, the study of ME3 has the potential to be a valuable model for the study of other neurodegenerative diseases.

In addition to its potential as a drug target, ME3 is also an important biomarker for the diagnosis and progression of neurodegenerative diseases. The defect in the protein tau is often detected using diagnostic tests, such as brain imaging studies or genetic testing. These tests can be used to determine if an individual has ME3 or to track the progression of the disease over time.

The study of ME3 has the potential to lead to the development of new treatments for a variety of neurodegenerative diseases. By understanding how the defect in the protein tau contributes to the progressive degeneration of the brain, researchers may be able to develop new treatments that target this protein and slow down or stop the progression of the disease.

In conclusion, ME3 is a drug target and biomarker of great interest to researchers because it provides insight into the role of mitochondria in the development and progression of neurodegenerative diseases. The study of ME3 has the potential to lead to the development of new treatments for a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Protein Name: Malic Enzyme 3

Functions: Catalyzes the oxidative decarboxylation of (S)-malate to pyruvate using NADP(+) as a cofactor (PubMed:7818469). Can also reverse the decarboxylation reaction, but only with significantly lower efficiency (PubMed:7818469)

The "ME3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ME3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets